Literature DB >> 25541667

Quilty effect after extracorporeal photopheresis in a patient with severe refractory cardiac allograft rejection.

Özgür Ulaş Özcan1, Tamer Sayın, Gürbey Soğut, Aylin Heper, Hüseyin Göksülük, Veysel Kutay Vurgun, Cansın Tulunay Kaya, Elif Ezgi Üstün, Osman İlhan, Çetin Erol.   

Abstract

Entities:  

Year:  2014        PMID: 25541667      PMCID: PMC4454065          DOI: 10.4274/tjh.2014.0052

Source DB:  PubMed          Journal:  Turk J Haematol        ISSN: 1300-7777            Impact factor:   1.831


× No keyword cloud information.

TO THE EDITOR

Solid organ transplant rejection is still a problem despite the use of immunosuppressive therapy. The currently available regimens for transplant rejection may predispose patients to malignancies such as nonmelanoma skin cancers and opportunistic infections [1]. Extracorporeal photopheresis (ECP) is a leukapheresis-based immunomodulatory therapy in which lymphocytes collected from the patient are incubated with 8-methoxypsoralen, a photosensitizing agent, in the presence of UV-A radiation and then reinfused into the patient [2]. Here we report a case of severe refractory cardiac allograft rejection that was successfully treated by ECP. A 47-year-old man presented with severe decompensated heart failure and hemodynamic compromise 13 months after heart transplantation. Ejection fraction was 25% with transthoracic echocardiography. After immediate therapy with positive inotropes and diuretics, diagnostic coronary angiography, right heart catheterization, and endomyocardial biopsy were performed. Coronary angiography revealed no obstructive coronary artery disease. The endomyocardial biopsy showed perivascular and interstitial lymphocytic inflammatory infiltrate with sparse eosinophils in 2 separate locations that were identified as moderate acute cellular rejection (ISHLT 2R). Cyclosporin A level was 150 ng/mL. Methylprednisolone pulses (1 g/day) for 3 days and equine anti-thymocyte globulin (Atgam) at 15 mg/kg/day were administered for induction therapy. Due to the deterioration of clinical status and intervening pneumonia, immunosuppressive therapy was ceased and ECP was planned. ECP sessions were performed twice a week for 2 months. After therapy the patient became minimally symptomatic with an ejection fraction of 50%. Repeated endomyocardial biopsy demonstrated lymphocytic aggregation confined to the endocardium, which was interpreted as Quilty effect, and remission of acute cellular rejection (Figure 1). The patient was discharged asymptomatically. Informed consent was obtained.
Figure 1

Endomyocardial biopsy specimen demonstrated endocardial lymphocytic aggregate.

Transplant rejection of solid organs remains an issue despite modern immunosuppressive regimens. The rate of rejection is 25% during the first year after heart transplantation [1]. Acute cell-mediated rejection is characterized by infiltration of T cells directed against the allograft [3]. Biopsy grades of >2 R warrant accentuation of immunosuppression [4]. ‘Quilty effect’ refers to lymphocytic infiltration in the endocardium of cardiac allografts. Although the clinical significance of the Quilty effect is not fully known, it is understood that the Quilty effect does not reflect transplant rejection. Hemodynamic compromise, persistence or recurrence of rejection, and side effects or complications associated with intensive immunosuppressive therapy necessitate alternative approaches for handling rejection. ECP is indicated for prevention of acute and chronic rejection of cardiac transplants [5,6,7]. Favorable effects were also demonstrated for secondary prevention among patients with a history of acute rejection [8]. ECP is a relatively safe procedure. Serious side effects are rarely reported, most of which are related to hypotension and anemia secondary to volume changes and blood loss during the procedure. Risks of opportunistic infections or secondary malignancies have not been increased because of ECP [9]. Small studies demonstrated the benefits of ECP for primary and secondary prevention of cardiac allograft rejection, but treatment for acute refractory cardiac allograft rejection is questionable because of the scarcity of data. We suggest the use of ECP for this compelling condition. Conflict of Interest Statement The authors of this paper have no conflicts of interest, including specific financial interests, relationships, and/or affiliations relevant to the subject matter or materials included.
  9 in total

1.  Prophylactic photopheresis and chronic rejection: effects on graft intimal hyperplasia in cardiac transplantation.

Authors:  M L Barr; C J Baker; F A Schenkel; S N McLaughlin; B C Stouch; V A Starnes; E A Rose
Journal:  Clin Transplant       Date:  2000-04       Impact factor: 2.863

2.  The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients.

Authors:  Maria Rosa Costanzo; Anne Dipchand; Randall Starling; Allen Anderson; Michael Chan; Shashank Desai; Savitri Fedson; Patrick Fisher; Gonzalo Gonzales-Stawinski; Luigi Martinelli; David McGiffin; Jon Smith; David Taylor; Bruno Meiser; Steven Webber; David Baran; Michael Carboni; Thomas Dengler; David Feldman; Maria Frigerio; Abdallah Kfoury; Daniel Kim; Jon Kobashigawa; Michael Shullo; Josef Stehlik; Jeffrey Teuteberg; Patricia Uber; Andreas Zuckermann; Sharon Hunt; Michael Burch; Geetha Bhat; Charles Canter; Richard Chinnock; Marisa Crespo-Leiro; Reynolds Delgado; Fabienne Dobbels; Kathleen Grady; W Kao; Jaqueline Lamour; Gareth Parry; Jignesh Patel; Daniela Pini; Jeffrey Towbin; Gene Wolfel; Diego Delgado; Howard Eisen; Lee Goldberg; Jeff Hosenpud; Maryl Johnson; Anne Keogh; Clive Lewis; John O'Connell; Joseph Rogers; Heather Ross; Stuart Russell; Johan Vanhaecke
Journal:  J Heart Lung Transplant       Date:  2010-08       Impact factor: 10.247

3.  Guidelines on the use of therapeutic apheresis in clinical practice--evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis.

Authors:  Zbigniew M Szczepiorkowski; Jeffrey L Winters; Nicholas Bandarenko; Haewon C Kim; Michael L Linenberger; Marisa B Marques; Ravindra Sarode; Joseph Schwartz; Robert Weinstein; Beth H Shaz
Journal:  J Clin Apher       Date:  2010       Impact factor: 2.821

4.  Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection.

Authors:  Susan Stewart; Gayle L Winters; Michael C Fishbein; Henry D Tazelaar; Jon Kobashigawa; Jacki Abrams; Claus B Andersen; Annalisa Angelini; Gerald J Berry; Margaret M Burke; Anthony J Demetris; Elizabeth Hammond; Silviu Itescu; Charles C Marboe; Bruce McManus; Elaine F Reed; Nancy L Reinsmoen; E Rene Rodriguez; Alan G Rose; Marlene Rose; Nicole Suciu-Focia; Adriana Zeevi; Margaret E Billingham
Journal:  J Heart Lung Transplant       Date:  2005-06-20       Impact factor: 10.247

5.  Extracorporeal photopheresis in the treatment of graft-versus-host disease: evidence and opinion.

Authors:  James W Hart; Lisa H Shiue; Elizabeth J Shpall; Amin M Alousi
Journal:  Ther Adv Hematol       Date:  2013-10

6.  Registry of the International Society for Heart and Lung Transplantation: Twenty-sixth Official Adult Heart Transplant Report-2009.

Authors:  David O Taylor; Josef Stehlik; Leah B Edwards; Paul Aurora; Jason D Christie; Fabienne Dobbels; Richard Kirk; Anna Y Kucheryavaya; Axel O Rahmel; Marshall I Hertz
Journal:  J Heart Lung Transplant       Date:  2009-10       Impact factor: 10.247

Review 7.  Update on extracorporeal photopheresis in heart and lung transplantation.

Authors:  Marisa B Marques; Joseph Schwartz
Journal:  J Clin Apher       Date:  2010-12-06       Impact factor: 2.821

8.  Rejection with hemodynamic compromise: objective evidence for efficacy of photopheresis.

Authors:  J K Kirklin; R N Brown; S T Huang; D C Naftel; S M Hubbard; B K Rayburn; D C McGiffin; R B Bourge; R L Benza; J A Tallaj; L J Pinderski; S V Pamboukian; J F George; M Marques
Journal:  J Heart Lung Transplant       Date:  2006-01-25       Impact factor: 10.247

9.  Photopheresis for the prevention of rejection in cardiac transplantation. Photopheresis Transplantation Study Group.

Authors:  M L Barr; B M Meiser; H J Eisen; R F Roberts; U Livi; R Dall'Amico; R Dorent; J G Rogers; B Radovancević; D O Taylor; V Jeevanandam; C C Marboe
Journal:  N Engl J Med       Date:  1998-12-10       Impact factor: 91.245

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.